How should I evaluate and manage a 24‑year‑old woman with elevated sex‑hormone‑binding globulin and normal total testosterone?

Evaluation and Management of Elevated SHBG with Normal Total Testosterone in a 24‑Year‑Old Woman

In a 24‑year‑old woman with elevated sex hormone‑binding globulin (SHBG) and normal total testosterone, you should measure free testosterone by equilibrium dialysis or calculate the free androgen index (FAI = total testosterone ÷ SHBG × 100), because elevated SHBG can mask true hyperandrogenism by binding testosterone and reducing its bioavailable fraction—even when total testosterone appears normal.

Understanding the Physiology

• SHBG is a glycoprotein synthesized primarily in the liver that binds testosterone and estradiol with high affinity, regulating their distribution between protein‑bound (inactive) and free (bioactive) states. 1
• Plasma SHBG concentrations are regulated by androgen/estrogen balance, thyroid hormones, insulin, and dietary factors; elevated SHBG is found in hyperthyroidism, hepatic cirrhosis, and with estrogen or thyroid hormone administration. 1, 2
• In women with suspected hyperandrogenism, relying solely on total testosterone can miss up to 30% of cases where total testosterone is normal but free testosterone or FAI is elevated. 3

Diagnostic Algorithm

Step 1: Confirm and Quantify Free Androgen Status

• Measure free testosterone using equilibrium dialysis (gold standard) or calculate FAI (total testosterone ÷ SHBG × 100). 3, 4
• An FAI < 30 indicates true hypogonadism even when total testosterone is borderline‑normal, whereas an FAI > 5% suggests hyperandrogenism in women. 5, 4
• Calculated free testosterone (CFT) using the Vermeulen equation is an acceptable alternative when equilibrium dialysis is unavailable; studies show 89% sensitivity and 83% specificity for detecting hyperandrogenism. 3, 4
• Avoid direct immunoassays for free testosterone in women because they are highly inaccurate at the low concentrations typical of the female range. 3

Step 2: Assess for Clinical Hyperandrogenism

• Evaluate for hirsutism (excessive terminal hair growth in male‑pattern areas), persistent or severe acne resistant to standard treatments, androgenic alopecia (male‑pattern hair loss), oligomenorrhea or amenorrhea, and infertility. 3
• Look for acanthosis nigricans (dark, velvety skin patches indicating insulin resistance), truncal obesity, and clitoromegaly (in severe cases). 3

Step 3: Second‑Line Androgen Testing (If First‑Line Results Are Equivocal)

• If total testosterone and free testosterone/FAI are not clearly elevated but clinical suspicion remains high, measure androstenedione (A4) (sensitivity 75%, specificity 71%) and DHEAS (sensitivity 75%, specificity 67%). 3
• Elevated DHEAS (>600 μg/dL) indicates an adrenal source and raises concern for adrenocortical carcinoma or androgen‑secreting tumors. 3

Step 4: Rule Out Secondary Causes of Elevated SHBG

• Measure TSH to exclude hyperthyroidism, which increases SHBG production and can mimic or coexist with hyperandrogenism. 3, 1, 2
• Assess liver function (AST, ALT, bilirubin, albumin) because hepatic cirrhosis elevates SHBG. 1
• Review medications: estrogens, thyroid hormone, and anticonvulsants (carbamazepine, phenobarbital, phenytoin) all increase SHBG. 3, 1
• Screen for HIV/AIDS in at‑risk populations, as this condition can elevate SHBG. 1

Step 5: Comprehensive Metabolic Screening

• Measure fasting glucose and perform a 2‑hour oral glucose tolerance test (75‑gram glucose load) to screen for diabetes and insulin resistance, which are common in PCOS. 3
• Obtain a fasting lipid panel (total cholesterol, LDL, HDL, triglycerides) to assess cardiovascular risk. 3
• Measure prolactin to exclude hyperprolactinemia, which can cause menstrual irregularity and hirsutism. 3
• Check LH and FSH: an LH/FSH ratio > 2 suggests PCOS. 3

Step 6: Imaging and Further Evaluation (If Indicated)

• Pelvic ultrasound is not required for diagnosis but may support PCOS if polycystic ovaries are present; however, isolated polycystic ovaries without clinical/biochemical hyperandrogenism and ovulatory dysfunction do not constitute PCOS. 3
• If testosterone is markedly elevated (>150–200 ng/dL) or symptoms develop rapidly with virilization (deepening voice, clitoromegaly), obtain pelvic and adrenal imaging (CT or MRI) to rule out androgen‑secreting tumors. 3

Interpretation of Results

Scenario A: Elevated FAI or Free Testosterone with Normal Total Testosterone

• This indicates functional hyperandrogenism due to elevated SHBG binding most of the circulating testosterone, leaving a disproportionately high free fraction. 3, 4
• The most common cause is polycystic ovary syndrome (PCOS), which accounts for 95% of hyperandrogenism cases in women of reproductive age. 3
• Studies show that 89.5% of PCOS patients have elevated FAI and 94.7% have elevated CFT, compared with only 36.4% having elevated total testosterone. 4

Scenario B: Normal FAI and Free Testosterone

• If free testosterone and FAI are normal, the elevated SHBG is likely due to a secondary cause (hyperthyroidism, liver disease, medications, or physiologic variation). 1, 2
• In this case, address the underlying cause (treat hyperthyroidism, optimize liver function, discontinue or substitute SHBG‑elevating drugs when feasible). 5

Management Strategy

If Hyperandrogenism Is Confirmed (Elevated FAI or Free Testosterone)

• Combined oral contraceptives (COCs) are first‑line treatment for hyperandrogenism, effectively regulating menstrual cycles and reducing androgen levels. 3
• Lifestyle modifications (hypocaloric diet with 500–750 kcal/day deficit, ≥150 min/week moderate‑intensity aerobic exercise plus resistance training 2–3 times/week) are essential for overweight/obese patients, as a 5–10% weight loss can significantly improve endogenous testosterone and insulin resistance. 5, 3
• Spironolactone (50–200 mg/day) can be added for persistent hirsutism or acne if COCs alone are insufficient. 3
• Address the psychological impact of hyperandrogenism symptoms (hirsutism, acne, alopecia) as part of comprehensive care. 3

If Hyperandrogenism Is Not Confirmed (Normal FAI and Free Testosterone)

• Treat the underlying cause of elevated SHBG (hyperthyroidism, liver disease, medication adjustment). 1, 2
• Reassure the patient that normal free testosterone indicates no androgen excess, and symptoms (if present) are likely unrelated to androgen metabolism. 3

Expected Outcomes

• When hyperandrogenism is confirmed and treated with COCs and lifestyle modifications, patients can expect improvement in hirsutism, acne, and menstrual regularity within 3–6 months. 3
• Metabolic parameters (insulin resistance, triglycerides, HDL cholesterol) may also improve with weight loss and hormonal therapy. 3

Critical Pitfalls to Avoid

• Do not diagnose hyperandrogenism based on total testosterone alone in the setting of elevated SHBG; always measure free testosterone or calculate FAI. 3, 4
• Do not omit thyroid function testing (TSH) when SHBG is elevated, as hyperthyroidism is a common and treatable cause. 3, 1
• Do not rely on direct immunoassays for free testosterone in women; use equilibrium dialysis or calculated FAI. 3
• Do not attribute symptoms to hyperandrogenism without biochemical confirmation, as symptoms are nonspecific and overlap with many conditions. 3
• Do not miss androgen‑secreting tumors by failing to image when testosterone is markedly elevated (>150–200 ng/dL) or virilization is present. 3

Monitoring and Follow‑Up

• Repeat free testosterone or FAI at 3–6 months after initiating treatment to assess response. 3
• Monitor metabolic parameters (fasting glucose, lipid panel) annually in PCOS patients due to increased cardiovascular and diabetes risk. 3
• Reassess symptoms (hirsutism, acne, menstrual regularity) at each visit to guide therapy adjustments. 3